Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05211674
Other study ID # M2S-ATTRACTION
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date February 2022
Est. completion date April 2023

Study information

Verified date January 2022
Source University of Rennes 2
Contact Romain Pichon, MSc
Phone 0667774267
Email r.pichon@ifpek.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Chronic Obstructive Pulmonary Disease (COPD) is a common chronic respiratory disease, causing disabling respiratory symptoms and impairing patients' quality of life. Currently one of the leading causes of death worldwide, COPD is a major socio-economic concern. It is also accompanied by extremely frequent extra-respiratory manifestations (or co-morbidities). Among these secondary manifestations, the equilibrium of these patients is subject to modifications: thus, numerous studies have shown that the equilibrium of COPD patients was altered compared to healthy age-matched subjects. This alteration is associated with a greater functional limitation and a higher risk of falling. Although this impairment has been demonstrated clinically, the balance of these patients has never been analysed using quantified movement analysis tools during tasks similar to those performed in daily life. Moreover, the underlying mechanisms remain unknown and the possible associations with several clinical factors of interest (pain, dyspnea, muscle function...) have not yet been assessed. The hypotheses of this project are that (1) the postural control of COPD patients is altered compared to healthy subjects during tasks of daily living and these changes can be characterised. (2) Several clinical factors are associated with these changes.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 32
Est. completion date April 2023
Est. primary completion date September 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - COPD patients GOLD stage 2 and 3 (A-D) - In accordance with Article L1121-8-1 of the Public Health Code, participants must be affiliated to a social security scheme or benefit from such a scheme. Exclusion Criteria: 1. the presence of long-term or exercise-based oxygen therapy, 2. the presence of a medically diagnosed pathology causing manifest disorders of balance, 3. the inability to walk 150 m without stopping and to climb or descend stairs, 4. a history of pneumonectomy or lobectomy within the last six months, 5. the existence of an acute respiratory exacerbation within the last two months, 6. the presence of obvious cognitive impairment that impairs comprehension of instructions, 7. body mass index less than 21 or more than 35 kg/m². 8. Person referred to in articles L. 1121-5 to L. 1121-8 and L. 1121-12 of the public health code: - Pregnant woman, woman in labour or nursing mother - Person deprived of liberty by judicial or administrative decision - Person hospitalised without consent and not subject to a legal protection measure, and person admitted to a health or social establishment for purposes other than research - Minor - Person subject to a period of exclusion for other research - Person of full age subject to a legal protection measure (guardianship, curatorship or safeguard of justice), person of full age unable to express their consent and not subject to a protection measure 9. Person under psychiatric care

Study Design


Related Conditions & MeSH terms


Intervention

Other:
quantified analysis of postural control during activities of daily living
functional tests that reproduce tasks of daily living (timed up and go test with and without dual cognitive task, modified Glittre ADL test)

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
University of Rennes 2 Rennes University Hospital

Outcome

Type Measure Description Time frame Safety issue
Other Dyspnea assessment scale assessed by the modified Borg Scale which is a 0 to 10 scale (0 representing no dyspnea, 10 representing the worst imaginable dyspnea). Dyspnea is assessed before, during and after the functional tests Clinical assessment at baseline
Other Heart rate assessed before, during and after functional tests Clinical assessment at baseline
Other Leg discomfort scale assessed on a 0 to 10 scale (0 representing no discomfort, 10 representing the worst imaginable discomfort).Leg discomfort is assessed before, during and after the functional tests Clinical assessment at baseline
Other Visual analog scale for pain Pain is assessed by a visual analog scale which is a 100mm long horizontal line with verbal descriptors at each end to express the extremes of the feeling (Here no pain and the worst imaginable pain) Clinical assessment at baseline
Other Pain Drawing scale participants are invited to identify on a body chart the location of experienced pain. Clinical assessment at baseline
Other Multi-dimensional dyspnea profile (MDP) Dyspnea assessment tool which investigates sensory and affective dimensions of dyspnea Clinical assessment at baseline
Other London chest activity of daily living questionnaire (LCADL) Dyspnea assessment tool which investigates the impact of dyspnea on 15 activities of daily living. A score from 0 to 5 is given for each activity, 5 representing an higher impact of dyspnea on the activity. Clinical assessment at baseline
Other Modified Medical Research Council Scale (MMRC) Dyspnea assessment tool which investigates impact of dyspnea in participants life. This is a 0 to 4 scale with descriptors associated to each number. 4 representing the most severe impact of dyspnea. Clinical assessment at baseline
Other Charlson Index Comorbidities assessment tool which list 19 potential comorbidities associated with a weighted score. The points are attributed when the comorbidity is present. A total score is then calculated. An higher score indicates an higher severity. Clinical assessment at baseline
Other Body composition Determination of fat free mass and fat mass by bioelectrical impedance analysis. Clinical assessment at baseline
Other Maximal inspiratory pressure inspiratory muscles strength assessment Clinical assessment at baseline
Other Falls Efficacy Scale - International Fear of falling assessment tool which investigates fear of falling in 16 different activities. Each activity is scored from 0 to 4 (4 representing an higher fear of falling in this activity). The total score range from 16 to 64 (an higher score indicating a most severe fear of falling) Clinical assessment at baseline
Other Number of anterior falls assessment of fall occurence in the last 12 months Clinical assessment at baseline
Other General Practioner assessment of Cognition (GP-COG) assessment of cognitive function. GP-COG gives a score from 0 to 9 (9 indicating a better cognitive function) Clinical assessment at baseline
Other International Physical Activity Questionnaire (IPAQ short-form) assessment of daily physical activity and sedentarity Clinical assessment at baseline
Other COPD assessment test (CAT) quality of life assessment tool Clinical assessment at baseline
Primary Margins of stability Postural control parameter related to the centre of mass (CoM) and the base of support of the participant, assessed during the functional tests Clinical assessment at baseline
Primary Margins of stability variability Coefficient of variation of a postural control parameter related to the centre of mass (CoM) and the base of support of the participant, assessed during the functional tests Clinical assessment at baseline
Primary Center of Mass velocity Parameter of participant's Centre of Mass (CoM) during the functional tests Clinical assessment at baseline
Primary Center of mass displacement Parameter of participant's Centre of Mass (CoM) during the functional tests Clinical assessment at baseline
Secondary Evolution of articular angulations Articular angulations assessed at the ankle, knee, hip, spine and thoracic level during the functional tests Clinical assessment at baseline
Secondary Centre of pressure (CoP) Area Parameter of participant's Centre of Pressure (CoP) during the sit to stand and stand to sit tasks of the Glittre-ADL test Clinical assessment at baseline
Secondary Centre of pressure (CoP) velocity Parameter of participant's Centre of Pressure (CoP) during the sit to stand and stand to sit tasks of the Glittre-ADL test Clinical assessment at baseline
Secondary Centre of pressure (CoP) variability Coefficient of variation of participant's Centre of Pressure (CoP) during the sit to stand and stand to sit tasks of the Glittre-ADL test Clinical assessment at baseline
Secondary Gait Cadence spatio-temporal parameter of gait assessed during the walking part of the Glittre-ADL test Clinical assessment at baseline
Secondary Gait velocity spatio-temporal parameter of gait assessed during the walking part of the Glittre-ADL test Clinical assessment at baseline
Secondary Gait phases duration spatio-temporal parameter of gait assessed during the walking part of the Glittre-ADL test Clinical assessment at baseline
Secondary Step width spatio-temporal parameter of gait assessed during the walking part of the Glittre-ADL test Clinical assessment at baseline
Secondary Step length spatio-temporal parameter of gait assessed during the walking part of the Glittre-ADL test Clinical assessment at baseline
Secondary Completion time of the Modified Glittre ADL Time to complete the modified Glittre-ADL test Clinical assessment at baseline
Secondary Completion time of the timed up and go test Time to complete the timed up and go test test Clinical assessment at baseline
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy